Carregando empresa
Just reported
Q3 2026 results
From Emergent Biosolutions's results release of 2 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 110M
-52% y/y
-53% q/qGuided
US$ 120M
midpoint
Within guide-8,3%EPS, GAAP
Actual
-US$ 0,64
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 37,3M
Guided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$ 600M – US$ 645M-16% y/y Lowered -5,7%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Emergent Biosolutions is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 33,9BA
NBIXNeurocrine Biosciences, Inc.US$ 17,2BA+
ELANElanco Animal Health IncorporatedUS$ 13,3BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,2BA+
LQDALiquidia CorporationUS$ 5,2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Emergent Biosolutions Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
